Skip to main content

Table 1 Tumor size changes in melanoma patients (Ipilimumab-Naive melanoma (KEYNOTE-006))

From: Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

  Number of Line of Therapy
1L 2L
n Median Mean Standard Deviation n Median Mean Standard Deviation
Pembrolizumab arm
 % of Early Tumor Sizes Changes (~Week 12) 282 −24.2 −19.7 42.5 152 −9.1 −9.0 47.2
 Best % of Tumor Size Changes 282 −53.0 −40.8 52.4 152 −36.3 −29.1 57.8
Ipilimumab arm
 % of Early Tumor Size Changes (~ Week 12) 124 7.8 6.6 46.0 61 −1.6 5.3 62.1
 Best % of Tumor Size Changes 124 −6.5 −7.0 56.2 61 −9.7 −6.8 70.2